The scientific community is increasingly scrutinizing the multifaceted biological roles of creatine, a naturally occurring compound renowned for its ergogenic properties in athletic performance, to ascertain its therapeutic applicability beyond physical enhancement. A comprehensive systematic review, meticulously published in the esteemed journal Brain Medicine, has delved into the existing body of clinical research to evaluate whether creatine’s capacity to bolster cellular energy reserves could translate into alleviating symptoms associated with depression.
This synthesized analysis, while providing a foundation for cautious optimism, underscores the significant knowledge gaps that persist. The compiled clinical trials have presented a dichotomous picture, with some investigations reporting notable improvements in depressive symptomatology and others yielding no discernible therapeutic effect, thus leaving researchers with more questions than definitive answers regarding its efficacy.
The investigative approach undertaken by the research team, spearheaded by Bassam Jeryous Fares from the University of Ottawa, eschewed the initiation of novel experimental protocols. Instead, the focus was placed on a rigorous examination of previously conducted studies. This meticulous review process identified six distinct research publications, encompassing five randomized controlled trials. In these trials, participants were administered either creatine or a placebo, with neither the participants nor the researchers aware of which substance was being provided – a methodology designed to mitigate bias.
These pivotal studies were geographically dispersed, originating from research institutions in South Korea, the United States, Brazil, Israel, and India. Collectively, the initial cohorts comprised 238 individuals. Of these, 126 participants were allocated to receive creatine, while 112 were assigned to the placebo group. The average age of the participants hovered around 36 years, and a notable demographic characteristic of the aggregated studies was the predominance of female participants; indeed, two of the included trials exclusively enrolled women.
The investigative scope of these trials varied, with four concentrating on individuals diagnosed with major depressive disorder, a chronic and often debilitating mental health condition. In contrast, one study extended its focus to participants experiencing depressive episodes within the context of bipolar disorder. The inherent heterogeneity in the design and methodological frameworks of these studies precluded a unified statistical aggregation of the collected data. Consequently, the researchers adopted an approach of individual study evaluation, meticulously assessing the findings of each trial independently.
Upon dissecting the assembled evidence, the systematic review unveiled a pattern of highly divergent outcomes across the examined depression studies.
Two of the five evaluated trials, both of which specifically involved women diagnosed with major depressive disorder, indicated that the administration of creatine yielded ancillary benefits. In one particularly noteworthy study, participants who received five grams of creatine daily in conjunction with the established antidepressant medication escitalopram demonstrated significantly greater amelioration of depressive symptoms over an eight-week period compared to their counterparts who received escitalopram combined with a placebo. This observed improvement was substantial when assessed by conventional statistical metrics, registering a Cohen’s d value of 1.13 on the Hamilton Depression Rating Scale, a widely recognized instrument for gauging depression severity. Furthermore, a larger proportion of participants in the creatine group achieved clinical remission, signifying a profound reduction in their symptoms.
In a separate trial, creatine was integrated as a complementary intervention alongside cognitive behavioral therapy (CBT), a form of psychotherapy. Participants who received creatine in conjunction with CBT exhibited a more pronounced decrease in depression symptoms, as measured by a standardized assessment tool, than those who underwent CBT treatment augmented by a placebo.
However, the remaining three trials presented a starkly different narrative, failing to demonstrate any statistically meaningful therapeutic advantage attributable to creatine supplementation.
One of these studies reported that neither a daily dose of five grams nor ten grams of creatine per day resulted in an improvement in symptoms for individuals whose depression had proven refractory to conventional pharmacological treatments. Another investigation found no discernible benefit over a placebo among adolescent girls, even when various dosages of creatine were explored. Similarly, a third trial, which focused on individuals with bipolar disorder experiencing a depressive phase, also concluded that creatine did not confer any symptomatic relief.
Beyond the efficacy data, the researchers also identified an important safety consideration. Two participants diagnosed with bipolar disorder who were administered creatine experienced episodes of hypomania or mania. This observation raises a crucial concern, suggesting that creatine might exert differential effects on individuals depending on their underlying psychiatric condition, potentially precipitating or exacerbating manic symptoms in susceptible populations.
The theoretical underpinnings for exploring creatine’s impact on depression are rooted in the brain’s exceptionally high metabolic demands. While creatine is widely recognized for its role in the rapid regeneration of adenosine triphosphate (ATP), the primary energy currency of cells, within muscle tissue, the brain also relies heavily on this fundamental energy pathway. Prior scientific inquiries have identified alterations in brain creatine metabolism among individuals suffering from mood disorders. These findings have prompted scientific curiosity into the possibility that dysfunctions in cellular energy production pathways could be a contributing factor to the pathophysiology of depression.
Furthermore, creatine has been hypothesized to influence the levels and activity of dopamine and serotonin, two critical neurotransmitters that play pivotal roles in regulating mood and are frequently targeted by contemporary antidepressant medications.
Despite these compelling theoretical connections, the authors of the review strongly emphasize that these proposed mechanisms remain largely speculative. The existing studies primarily reveal correlations, rather than providing definitive causal evidence, that altered creatine metabolism directly contributes to the onset or perpetuation of depression. The complex nature of depression, a disorder involving intricate interactions across multiple biological pathways, further complicates the search for single-factor solutions.
"The signal we are observing is intriguing, but it is not yet a definitive verdict," stated Bassam Jeryous Fares, the lead author of the review and a student at the University of Ottawa’s Faculty of Medicine. He elaborated, "The fact that two trials pointed in one direction and three trials pointed in another signifies that this is not the kind of evidence upon which one would advocate for a change in clinical practice. Instead, it is the type of outcome that suggests the question warrants more in-depth exploration."
Nicholas Fabiano, the corresponding author of the review and a psychiatry resident at the University of Ottawa, echoed this sentiment, urging for continued caution. "Creatine appears to be a safe intervention based on the available data. The adverse events we identified were largely confined to mild gastrointestinal discomfort. At this juncture, we cannot definitively assert that creatine reliably assists with depressive symptoms, nor can we definitively state whether these findings are generalizable to the broader population."
The researchers unequivocally stress that the current evidentiary foundation is too limited to support the routine recommendation of creatine supplementation for the management of depression. The clinical trials reviewed were generally characterized by relatively small sample sizes, a disproportionate representation of women compared to men, and variability in their methodological rigor. While two of the studies were assessed as having a low risk of bias, the remaining three raised certain concerns, primarily related to the procedures for participant allocation and the handling of missing data. Consequently, the conclusions drawn from these studies cannot be broadly applied to diverse patient populations or clinical settings.
The review advocates for the implementation of larger-scale and longer-duration clinical trials that extend beyond the typical eight-week treatment period. The researchers also recommend investigating the synergistic effects of creatine when combined with exercise interventions, recognizing the profound impact of physical activity on mental well-being. Furthermore, future research should explore whether different dosages of creatine might yield superior outcomes, while also acknowledging that simply increasing the dosage does not inherently guarantee enhanced benefits.
Insights from animal studies may offer additional avenues for understanding. Preclinical experiments have indicated that creatine can differentially affect depression-like behaviors in male and female rodents. This observed sex-specific effect in animal models could potentially shed light on why the human studies that predominantly featured female participants yielded the most robust positive results.
For the present time, creatine remains an avenue of significant scientific interest rather than a conclusively proven therapeutic modality for depression. A dietary supplement long associated with enhancing physical prowess and muscle development is now capturing the attention of scientists actively seeking novel and effective strategies for addressing the complex challenges of depression.
The peer-reviewed research article, titled "Creatine as a treatment for depression," was published in Brain Medicine and has been made accessible through Open Access, with its availability commencing on June 30, 2026.
About the Author
